Immunoscore provides prognostic information in low (T1-3N1) and high risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)
- Citation:
- J Clin Oncol vol 36 (suppl 4S) asbstr 614
- Meeting Instance:
- ASCO GI 2018
- Year:
- 2018
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Eli Lilly and Company, Pfizer, Bristol-Myers Squibb
- Grants:
- U10CA180821, U10CA180882, U10CA180820, U10CA180863, U10CA180888, CCSRI 021039
- Corr. Author:
- Authors:
- Frank A. Sinicrope Qian Shi Fabienne Hermitte Erica N. Heying Al B. Benson Sharlene Gill Richard M. Goldberg Morton S. Kahlenberg Suresh G. Nair Anthony F. Shields Daniel J. Sargent Jérôme Galon Steven R. Alberts
- Networks:
- Study
- NCCTG-N0147
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: